| 2.24 0.04 (1.82%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.97 | 1-year : | 3.47 |
| Resists | First : | 2.54 | Second : | 2.97 |
| Pivot price | 2.03 |
|||
| Supports | First : | 1.99 | Second : | 1.64 |
| MAs | MA(5) : | 2.31 |
MA(20) : | 1.97 |
| MA(100) : | 1.7 |
MA(250) : | 1.41 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 72.4  |
D(3) : | 81.3 |
| RSI | RSI(14): 54.9 |
|||
| 52-week | High : | 3.58 | Low : | 1 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NNVC ] has closed below upper band by 30.0%. Bollinger Bands are 38.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.35 - 2.36 | 2.36 - 2.37 |
| Low: | 2.14 - 2.15 | 2.15 - 2.16 |
| Close: | 2.22 - 2.24 | 2.24 - 2.25 |
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Tue, 23 Jul 2024
Reviewing Nuvectis Pharma (NASDAQ:NVCT) and NanoViricides (NYSE:NNVC) - Defense World
Thu, 18 Jul 2024
NanoViricides (NYSE:NNVC) Downgraded to “Sell” at StockNews.com - Defense World
Wed, 10 Jul 2024
NanoViricides (NYSE:NNVC) Shares Down 0.6% - Defense World
Tue, 14 May 2024
NanoViricides shares gain as new data shows lead drug asset's strong activity against RSV | NYSE-A:NNVC - Proactive Investors USA
Mon, 13 May 2024
NanoViricides CEO discusses NV-387’s broad-spectrum antiviral potential - Proactive Investors USA
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 4.6 (%) |
| Held by Institutions | 10.1 (%) |
| Shares Short | 317 (K) |
| Shares Short P.Month | 273 (K) |
| EPS | -0.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -31.2 % |
| Return on Equity (ttm) | -52.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.74 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -2.91 |
| PEG Ratio | 0 |
| Price to Book value | 2.03 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|